Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement

This article was originally published in The Pink Sheet Daily

Executive Summary

What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December but not yet launched.

You may also be interested in...



US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo

FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.

US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo

FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.

Keeping Track: New Indication For Lucentis; New Lesinurad Application From Ironwood

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel